

Published in final edited form as:

*Brain Behav Immun.* 2013 February ; 28: 16–24. doi:10.1016/j.bbi.2012.09.004.

## Omega-3 Fatty Acids, Oxidative Stress, and Leukocyte Telomere Length: A Randomized Controlled Trial

Janice K. Kiecolt-Glaser<sup>a,1</sup>, Elissa S. Epel<sup>b</sup>, Martha A. Belury<sup>c</sup>, Rebecca Andridge<sup>d</sup>, Jue Lin<sup>e</sup>, Ronald Glaser<sup>a</sup>, William B. Malarkey<sup>a</sup>, Beom Seuk Hwang<sup>d</sup>, and Elizabeth Blackburn<sup>e</sup>

<sup>a</sup>Institute for Behavioral Medicine Research, The Ohio State University College of Medicine, Columbus, OH 43210

<sup>b</sup>Department of Psychiatry, University of California, San Francisco, San Francisco, CA, 94143

<sup>c</sup>Department of Human Nutrition, The Ohio State University, Columbus, OH 43210

<sup>d</sup>Division of Biostatistics, The Ohio State University College of Public Health, Columbus, OH 43210

<sup>e</sup>Department of Biochemistry and Biophysics, University of California, San Francisco, San Francisco, CA, 94158

### Abstract

Shorter telomeres have been associated with poor health behaviors, age-related diseases, and early mortality. Telomere length is regulated by the enzyme telomerase, and is linked to exposure to proinflammatory cytokines and oxidative stress. In our recent randomized controlled trial, omega-3 (*n*-3) polyunsaturated fatty acid (PUFA) supplementation lowered the concentration of serum proinflammatory cytokines. This study assessed whether *n*-3 PUFA supplementation also affected leukocyte telomere length, telomerase, and oxidative stress. In addition to testing for group differences, changes in the continuous *n*-6:*n*-3 PUFA ratio were assessed to account for individual differences in adherence, absorption, and metabolism. The double-blind 4-month trial included 106 healthy sedentary overweight middle-aged and older adults who received (1) 2.5 g/day *n*-3 PUFAs, (2) 1.25 g/day *n*-3 PUFAs, or (3) placebo capsules that mirrored the proportions of fatty acids in the typical American diet. Supplementation significantly lowered oxidative stress as measured by F2-isoprostanes ( $p=0.02$ ). The estimated geometric mean log-F2-isoprostanes values were 15% lower in the two supplemented groups compared to placebo. Although group differences for telomerase and telomere length were nonsignificant, changes in the *n*-6:*n*-3 PUFA plasma ratios helped clarify the intervention's impact: telomere length increased with decreasing *n*-6:*n*-3 ratios,  $p=0.02$ . The data suggest that lower *n*-6:*n*-3 PUFA ratios can impact cell aging. The triad of inflammation, oxidative stress, and immune cell aging represents important pre-disease mechanisms that may be ameliorated through nutritional interventions. This translational research broadens our understanding of the potential impact of the *n*-6:*n*-3 PUFA balance.

ClinicalTrials.gov identifier: NCT00385723

© 2012 Elsevier Inc. All rights reserved.

<sup>1</sup>Address correspondence to Janice K. Kiecolt-Glaser, Ph.D., Institute for Behavioral Medicine Research, The Ohio State University College of Medicine, 460 Medical Center Drive, Columbus, OH 43210, USA; Janice.Kiecolt-Glaser@osumc.edu.

Conflict of interest statement: Drs. Blackburn, Epel, and Lin are co-founders in Telome Health, Inc, a telomere measurement company.

**Publisher's Disclaimer:** This is a PDF file of an unedited manuscript that has been accepted for publication. As a service to our customers we are providing this early version of the manuscript. The manuscript will undergo copyediting, typesetting, and review of the resulting proof before it is published in its final citable form. Please note that during the production process errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.

## Keywords

omega-3; omega-6; telomeres; inflammation; cell aging; nutritional neuroscience; oxidative stress; F2-isoprostanes; fish oil

## 1. Introduction

### 1.1 Telomeres, Telomerase, Inflammation, and Oxidative Stress

Telomeres, the caps found at the ends of chromosomes, are essential for chromosomal stability and replication; the enzyme telomerase is important for telomere formation, maintenance, and restoration (Blackburn, 2005; Epel et al., 2004). A growing literature has linked shorter telomeres with health behaviors, age-related diseases, and earlier mortality (Brouillette et al., 2003; Epel et al., 2009; Kimura et al., 2008; Valdes et al., 2005).

Telomeres can be maintained or lengthened by telomerase, an intra-cellular enzyme that adds telomeric DNA to shortened telomeres (Chan and Blackburn, 2003). Telomere length is also linked to, and likely regulated by, exposure to proinflammatory cytokines and oxidative stress (Aviv, 2006; Carrero et al., 2008; Damjanovic et al., 2007). Inflammation triggers T-cell proliferation, one known cause of telomere shortening (Aviv, 2004; Carrero et al., 2008; Gardner et al., 2005). Oxidative stress promotes telomere erosion during cellular replication *in vitro* and also stimulates the synthesis of proinflammatory cytokines (Aviv, 2006; Lipcsey et al., 2008).

### 1.2 Telomeres, Telomerase, and Omega-3 PUFAs

Although telomeres typically shorten with aging, shortening is not inevitable, and telomeres can also lengthen (Aviv et al., 2009; Ehrlenbach et al., 2009; Epel et al., 2009; Farzaneh-Far et al., 2010a; Nordfjall et al., 2009). It is important to identify malleable factors that might promote telomere stability over time. Based on theoretical and empirical reasons, it is possible that blood levels of polyunsaturated fatty acids (PUFAs) may be one of the factors that can prevent telomere shortening over time. The omega-3 (*n*-3) PUFAs can reduce inflammation and decrease oxidative stress (Calder, 2005; Kiecolt-Glaser et al., 2011; Mori et al., 1999; Nalsen et al., 2006), described below, and thus could buffer telomeres from their damaging effects.

In the Heart and Soul Study, which followed 608 people with stable coronary heart disease over five years, average telomere length increased in 23% of the individuals, shortened in 45%, and remained unchanged in 32% (Farzaneh-Far et al., 2010a). Slower telomere attrition was predicted by higher baseline levels of the two key *n*-3 PUFAs, eicosapentaenoic acid (EPA) and docosahexanoic acid (DHA), which were the only significant predictors out of 16 clinical and behavioral factors examined (Farzaneh-Far et al., 2010b). Each standard deviation increase in the DHA+EPA total was associated with a 32% reduction in the odds of telomere attrition. In a different pilot study, an intensive three-month lifestyle change program that included *n*-3 PUFA supplementation significantly increased telomerase activity (Ornish et al., 2008).

Dietary intakes of both the *n*-3 and omega-6 (*n*-6) PUFAs influence inflammation. Arachidonic acid (AA) is an *n*-6 PUFA that may be derived from its precursor, linoleic acid, found in popular dietary oils such as corn, sunflower, and safflower oils. The eicosanoids produced from AA increase proinflammatory cytokine production (Calder, 2005). In contrast, the eicosanoids derived from EPA, a long chain *n*-3 PUFA found in cold water fish oils, curb the production of AA-derived eicosanoids (Calder, 2005). Thus, both higher plasma levels of *n*-3 PUFAs as well as lower plasma *n*-6:*n*-3 PUFA ratios restrain

proinflammatory cytokine production (Kiecolt-Glaser et al., 2007). Accordingly, it is not surprising that both higher levels of *n*-3 PUFAs as well as lower *n*-6:*n*-3 PUFA ratios have been associated with lower proinflammatory cytokine production in epidemiological and observational studies (Farzaneh-Far et al., 2009; Ferrucci et al., 2006; Kalogeropoulos et al., 2010; Kiecolt-Glaser et al., 2007).

### 1.3 The present study

In our recent 4-month randomized controlled trial (RCT), serum interleukin 6 (IL-6) decreased by 10% and 12% in our low (1.25 g/day) and high (2.5 g/day) dose *n*-3 PUFA groups, respectively, compared to a 36% increase in the placebo group (Kiecolt-Glaser et al., 2012). Similarly, low and high dose *n*-3 PUFA groups showed modest 0.2% and -2.3% changes in serum TNF- $\alpha$ , in contrast to the 12% increase in the control group. Depressive symptoms, the other primary trial outcome, were low at baseline and did not change. This study assessed the impact of *n*-3 PUFA supplementation, and consequent changes in the *n*-6:*n*-3 PUFA ratio, on secondary outcomes in our RCT: leukocyte telomere length, telomerase, and oxidative stress.

## 2. Methods

### 2.1 Participants

Blood samples were obtained from 106 men and women, ages 40–85 (Table 1) who were part of the 138 participants in the parent *n*-3 PUFA RCT (ClinicalTrials.gov identifier: NCT00385723); no blood samples were available from the early participants for these analyses. Campus and community print and web-based announcements were used for recruitment. The Ohio State University biomedical institutional review board approved this study, and each participant provided written informed consent.

The online screening form assessed health history, medications, and health behaviors. Exclusions included psychoactive drugs or mood altering medications, lipid-altering drugs, cardiovascular medications, steroids, prostaglandin inhibitors, heparin, warfarin, regular use of non-steroidal anti-inflammatory drugs other than a daily aspirin, and alcohol/drug abuse. We also excluded pregnant or nursing women, vegetarians, diabetics, people who routinely took fish oil or flaxseed supplements or ate more than two portions of oily fish per week, smokers, and individuals with recurrent digestive problems, convulsive disorders, and autoimmune and/or inflammatory diseases. Individuals were excluded if they typically engaged in 2 or more hours of vigorous physical activity per week or had a body mass index (BMI) below 22.5 or over 40.

In addition, we used participants' ability to follow the supplementation regimen as a criterion for study entry. Participants received a 7-day supply of placebo capsules (single blind) at the in-person screening session, and those who had taken less than 80% of the capsules a week later were dropped before randomization. The most common medications among our 106 subjects were, in order, nonprescription NSAIDs ( $n=14$ ; 8 aspirin, 4 ibuprofen, 2 naproxen), levothyroxine ( $n=8$ ), estrogen with or without progesterone ( $n=8$ ), and antacids ( $n=7$ ), and these did not differ by group. Individuals were excluded if they typically engaged in 2 or more hours of vigorous physical activity per week or had a body mass index (BMI) below 22.5 or over 40.

### 2.2 Design and Study Components

Data collection for this double-blind placebo-controlled four month RCT began in September, 2006 and ended in February, 2011. At baseline and at 4 months we assessed telomere length, telomerase, and oxidative stress. Blood samples were collected between

7:00 and 9:00 AM to control for diurnal variation. Samples were obtained in the Ohio State Clinical Research Center, a hospital research unit. Attrition was minimal; only 5 of 138 subjects in the parent study failed to complete the full trial (Kiecolt-Glaser et al., 2012).

**2.21 Supplement and Placebo**—This RCT compared responses to A) 2.5 g/day *n*-3 PUFA, B) 1.25 g/day *n*-3 PUFA, or C) placebo. We chose a 7:1 EPA:DHA balance because of evidence that EPA has relatively stronger anti-inflammatory and antidepressant effects than DHA (Ariel and Serhan, 2007; Lin et al., 2010b; Sijben and Calder, 2007); thus, the high dose group received 2085 mg/d of EPA and 348 mg/d of DHA. The placebo was a mixture of palm, olive, soy, canola, and coco butter oils that approximated the saturated:monounsaturated:polyunsaturated ratio consumed by US adults, 37:42: 21 (USDA Continuing Survey of Food Intake by Individuals, 1994–1996). OmegaBrite (Waltham, MA) supplied both the *n*-3 PUFA and the matching placebo; all supplements were coated with a fuchsia coloring. OmegaBrite added a mild fish flavor to the placebo to help disguise any differences between the *n*-3 PUFAs and the placebo, and we told participants about the fish flavoring to promote blindness (Stoll et al., 2001). Both the placebo and the *n*-3 PUFA pills included 1 IU of vitamin E. In order to ensure integrity of the oil supplements, dietary oils were analyzed every 6–8 months by gas chromatography of methylated fatty acids prepared in the Belury lab. Table 2 shows a typical fatty acid composition of the dietary supplements (% fatty acid of total fatty acids detected for analysis).

**2.22 Randomization and Masking**—Before a participant left the baseline session, s/he was randomly assigned to one of three treatment groups using a permuted block randomization sequence prepared and maintained by the data manager who had no involvement in data collection or biological laboratory analyses; she was the only person who had access to the randomization list. The active and placebo study supplements were packaged according to the randomization sequence, so that a participant was randomized to the next available individual supplement package. At each subsequent study visit, participants returned unused supplements and received the next month's supply. Adherence was excellent and did not differ between active and placebo groups, with 3.3%, 2.0%, and 2.6% percent of unused supplements returned in the placebo, low, and high dose groups, respectively ( $p=0.31$ ). Analysis of data from both participants and experimenters showed adequate blinding as previously described (Kiecolt-Glaser et al., 2012)

### 2.3 Anthropometry and Health-Related Behaviors

Sagittal abdominal diameter (SAD) measurements at baseline provided data on abdominal fat. Validation studies have demonstrated SAD's utility as a noninvasive central adiposity measure (Clasey et al., 1999).

Participants completed the Women's Health Initiative Food Frequency Questionnaire at the screening session and at 4 months. It provided data on foods and beverages consumed in the past 90 days (Patterson et al., 1999).

The Pittsburgh Sleep Quality Index, administered at baseline and 4 months, assessed sleep quality and disturbances over a one-month interval (Buysse et al., 1989). It has good diagnostic sensitivity and specificity (Buysse et al., 1989).

The Community Healthy Activities Model Program for Seniors Questionnaire assessed the frequency and duration of various physical activities at baseline and 4 months. An excellent instrument for middle-aged and older populations, it is sensitive to relatively small changes in physical activity (Stewart et al., 2001).

## 2.4 Depressive Symptoms and Syndromal Mood Disorders

The Center for Epidemiological Studies Depression Scale is a widely-used measure of depressive symptomatology (Radloff, 1977). The Structured Clinical Interview for DSM-IV (SCID) mood disorder modules, administered during screening, provided baseline data on both lifetime and current mood disorders (First et al., 1996); the visit 4 SCID assessed the subsequent development or resolution of symptoms.

## 2.5 Fatty Acid Analyses

Lipids were extracted from plasma using chloroform: methanol (2:1, v/v) with 0.2 vol. 0.88% KCl (Bligh and Dyer, 1959). Fatty acid methyl esters of the fractions were prepared by incubating the fractions with tetramethylguanidine at 100°C (Shantha et al., 1993) and analyzed by gas chromatography (Shimadzu, Columbia, MD) using a 30-m Omegawax 320 (Supelco-Sigma) capillary column. The helium flow rate was 30 ml/min and oven temperature ramped beginning at 175°C and held for 4 min then increased to 220°C at a rate of 3°C/min as previously described (Belury and Kempa-Steczko, 1997). Retention times were compared to authentic standards for fatty acid methyl esters (Supelco-Sigma, St. Louis, MO and Matreya, Inc, Pleasant Gap, PA). We report fatty acids that were greater than 0.01% of peaks detected; these included myristate (14:0), palmitate (16:0), palmitoleate (16:1n7), stearate (18:0), oleate (18:1n9), vaccenate (18:1n7), linoleate (18:2n6), gamma-linolenate (18:3n6), alpha-linolenate (18:3n3), stearidonate (18:4n3), catoleate (20:1n9), eicosadienoate (20:2n6), dihomo-gamma-linolenate (20:3n6), arachidonate (20:4n6), eicosapentaenoate (20:5n3), adrenate (22:4n6), docosapentaenoate (22:5n3), and docosahexaenoate (22:6n3). For calculating the *n*-6:*n*-3 ratio, all identified *n*-6 and *n*-3 fatty acids were used.

## 2.6 Telomere Length

Peripheral blood lymphocytes (PBL) were purified from whole blood by density-gradient centrifugation in Lymphocyte Separation Medium (Mediatech, Inc.). PBLs ( $2 \times 10^6$  cells) were lysed in 300ul lysis buffer (included in Genra Puregene cell kit from Qiagen) and genomic DNA isolation was performed following the company's instruction. The quality and quantity of the genomic DNA were determined using 260/280 UV spectrophotometry and Picogreen Assay. The telomere length measurement assay is adapted from the published original method by Cawthon. (Cawthon, 2002; Lin et al., 2010a) The telomere thermal cycling profile consists of: Cycling for T (telomic) PCR: denature at 96°C for 1 second, anneal/extend at 54°C for 60 seconds, with fluorescence data collection, 30 cycles. Cycling for S (single copy gene) PCR: denature at 95°C for 15 seconds, anneal at 58°C for 1 second, extend at 72°C for 20 seconds, 8 cycles; followed by denature at 96°C for 1 second, anneal at 58°C for 1 second, extend at 72°C for 20 seconds, hold at 83°C for 5 seconds with data collection, 35 cycles.

The primers for the telomere PCR are *tel1b* [5'-CGGTTT(GTTTGG)<sub>5</sub>GTT-3'], used at a final concentration of 100 nM, and *tel2b* [5'-GGCTTG(CCTTAC)<sub>5</sub>CCT-3'], used at a final concentration of 900 nM. The primers for the single-copy gene (human beta-globin) PCR are *hbg1* [5' GCTTCTGACACAACACTGTGTTCACTAGC-3'], used at a final concentration of 300 nM, and *hbg2* [5'-CACCAACTTCATCCACGTTCCACC-3'], used at a final concentration of 700 nM. The final reaction mix contains 20 mM Tris-HCl, pH 8.4; 50 mM KCl; 200 μM each dNTP; 1% DMSO; 0.4x Syber Green I; 22 ng E. coli DNA per reaction; 0.4 Units of Platinum Taq DNA polymerase (Invitrogen Inc.) per 11 microliter reaction; 0.5 – 10 ng of genomic DNA. Tubes containing 26, 8.75, 2.9, 0.97, 0.324 and 0.108ng of a reference DNA (from HeLa cancer cells) are included in each PCR run so that the quantity of targeted templates in each sample can be determined relative to the reference DNA sample

by the standard curve method. Each concentration of the reference DNA is run as quadruplets and samples are run as triplicates.

To control for inter-assay variability, 8 control DNA samples from cancer cell lines (including 293T, H1299, UMUC3, and UMUC3 cells infected with a lentiviral construct containing the telomerase RNA gene to extent telomeres, harvested at various population doublings after infection) are included in each run. In each batch, the T/S ratio of each control DNA is divided by the average T/S for the same DNA from 10 runs to get a normalizing factor. This is done for all 8 samples and the average normalizing factor for all 8 samples is used to correct the participant DNA samples to get the final T/S ratio. The T/S ratio for each sample is measured twice, each time in triplicate wells. When the duplicate T/S value and the initial value vary by more than 7%, the sample is run the third time and the two closest values will be reported. The formula to convert the T/S ratio to base pairs is  $\text{base pairs} = 3,274 + 2,413 * (T/S)$ . The inter-assay coefficient of variation for telomere length measurement was 4.3% for this study.

## 2.7 Telomerase Activity

PBLs were purified from whole blood as above. Cells were lysed with 1XCHAPS buffer (10 mM Tris.HCl, pH 7.5, 1mM MgCl<sub>2</sub>, 1 mM EGTA, 0.1 mM Benzamidine, 5 mM b-mercaptoethanol, 0.5% CHAPS, 10% glycerol) on ice for 30 minutes and spun at 4°C at 14k rpm for 20 minutes to generate an extract corresponding to 10000 cells/ul. Extracts were stored at -80 degree for batch analysis of telomerase activity. Telomerase activity was measured by the TRAPeze Telomerase detection kit (Millipore, Cat# S7700) using a modified protocol developed by the Blackburn lab.(Lin et al., 2010a) Three concentrations (2000, 5000 and 10000 cells) were used for TRAP reactions to ensure that the assay was in the linear range. Details of the method are published elsewhere.(Lin et al., 2010a) The inter-assay coefficient of variation (CV) was 6.8%.

## 2.8 Oxidative Stress

F<sub>2</sub>-isoprostanes provide the most reliable index of *in vivo* oxidative stress when compared to other well-known biomarkers (Milne et al., 2007). Plasma samples were analyzed by Vanderbilt's Eicosanoid Core Laboratory, following their published protocol (Milne et al., 2007).

## 2.9 Statistical Methods

Baseline subject characteristics and outcomes at baseline were compared across supplementation groups using ANOVA and chi-square tests as appropriate. Continuous variables that were right-skewed were natural logarithm transformed (telomerase, F<sub>2</sub>-isoprostanes) to better approximate normality of residuals. Where appropriate, Pearson correlations and Spearman correlations (skewed variables) were used to describe cross-sectional associations between continuous measures. Analysis of covariance was used to separately model change in telomerase (N=94), telomere length (N=106), and F<sub>2</sub>-isoprostanes (N=97) from baseline to 4 months, adjusting for baseline levels, using all subjects with available four-month follow-up data. In order to control Type I error, the Tukey-Kramer method was used for between-group comparisons. Although supplementation group was the main predictor of interest, secondary analyses used change in continuous *n*-6:*n*-3 PUFA ratio in place of group because individuals differ in absorption and metabolism of *n*-3 PUFA supplements, as well as in adherence. Despite the relative balance between the groups due to the randomization, analyses were repeated controlling for age, gender, and sagittal abdominal diameter (SAD). Alpha was set to 0.05, and two-sided tests were conducted. All analyses were carried out in SAS version 9.3 (SAS Institute, Cary, NC).

### 3. Results

#### 3.1 Study population, baseline data

Table 1 shows baseline characteristics of the analysis sample (N = 106), with 31 subjects in the placebo arm, 40 in the low dose fish oil arm, and 35 in the high dose fish oil arm. Randomization produced groups that did not differ on age, baseline FFQ dietary variables, sleep quality, depressive symptoms, and history of major depressive disorder,  $p > 0.19$  for all tests. There were no baseline group differences on SAD or BMI ( $p > 0.60$  for both). Using BMI cut points of 25 and 30 kg/m<sup>2</sup>, 100 participants (94%) were overweight, and 54 (51%) were obese. Groups were similar on telomere length, telomerase, and F2-isoprostanes at baseline ( $p > 0.26$  for all tests).

#### 3.2 Changes in fatty acids

Baseline levels of plasma fatty acids and changes over time are shown in Table 3. EPA and DHA levels were low (~0.5% and ~1.5% respectively), and there were no group differences in EPA, DHA, total *n*-3 PUFA, or *n*-6:*n*-3 PUFA ratio at baseline. There were small differences in total *n*-6 PUFA across groups ( $p = 0.01$ ) with slightly lower levels at baseline in the 1.25 g/d *n*-3 PUFA group. By month four plasma levels of EPA were approximately 3.5-fold higher in the 1.25 g/d *n*-3 group and 6-fold higher in the 2.5 g/d *n*-3 group ( $p < 0.0001$  for both), and plasma DHA levels were approximately 1.7-fold higher in the 1.25 g/d *n*-3 PUFA group and 2-fold higher in the 2.5 g/d *n*-3 PUFA group ( $p < 0.0001$  for both). The placebo group experienced a small increase in EPA, with plasma EPA levels approximately 1.5-fold higher ( $p = 0.001$ ), but had no change in DHA ( $p = 0.47$ ). The *n*-6:*n*-3 PUFA ratio was significantly decreased after supplementation for both low and high dose groups, dropping from 10 to 6.8 in the 1.25 g/d *n*-3 PUFA group and from 11 to 5.0 in the 2.5 g/d *n*-3 PUFA group ( $p < 0.0001$  for both). The placebo group experienced a much smaller decrease of borderline significance, dropping from 11 to 10 ( $p = 0.06$ ).

#### 3.3 Changes in F2-isoprostanes

Table 4 shows the significant group differences in changes in log-F2-isoprostanes after supplementation. The estimated mean change in log-F2-isoprostanes was 0.073 for the placebo group, corresponding to an 8% increase in geometric mean. In contrast, the estimated mean change in log-F2-isoprostanes was -0.094 for the low dose group and -0.086 for the high dose group, corresponding to decreases in the geometric mean of 9% and 8%, respectively. For both doses these changes were significantly different than the placebo group (Tukey-Kramer adjusted  $p = 0.02$ ;  $p = 0.04$ , respectively), resulting in the intervention groups having a 15% lower geometric mean F2-isoprostanes at 4 months compared to control. There was not a significant difference between the two supplemented groups ( $p = 0.99$ ). These results remained the same in analyses additionally controlling for age, gender and SAD.

#### 3.4 Changes in telomere length and telomerase

The adjusted mean change in telomere length, expressed in base pairs (bp), was an increase of 21 bp for the low dose group and an increase of 50 bp in the high dose group compared to a decrease of 43 bp for placebo (Table 4); however, differences between the groups were not significant. Telomere lengthening (defined as a positive change) was observed in 54% (n=19) of the 2.5 g/d *n*-3 PUFA group and 53% (n=21) of the 1.25 g/d *n*-3 PUFA group, but only 39% (n=12) of the placebo group, though these differences were not significant ( $p = 0.39$ ). There were no differences among the groups in change in telomerase activity at four months (Table 4). Models additionally controlling for age, gender, and SAD produced similar results.

### 3.5 Changes in telomere length based on n-6:n-3 PUFA plasma ratios

Secondary analyses explored the effect of changes in plasma n-6:n-3 PUFA ratios on changes in telomere length, since individuals differ in absorption and metabolism of n-3 PUFA supplements. Table 5 shows the resulting linear regression analysis, controlling for baseline telomere length and baseline n-6:n-3 PUFA ratio. A one unit decrease in n-6:n-3 PUFA ratio was associated with an estimated 20 bp increase in telomere length ( $p = 0.02$ ).

The analysis was repeated using the change in AA:(EPA+DHA) ratio in place of n-6:n-3 PUFA ratio; the AA:(EPA+DHA) ratio is favored by some researchers because of a more direct tie to eicosanoid metabolism. Since the change in AA:(EPA+DHA) ratio was highly correlated with the change in n-6:n-3 PUFA ratio ( $r = 0.90$ ,  $p < 0.001$ ), results were similar, with a one unit decrease in AA:(EPA+DHA) ratio associated with a 35 bp increase in telomere length ( $p = 0.08$ ). Similarly, when the change in the sum of EPA, DHA, and DPA was used in place of either ratio, results were again comparable, with a one unit increase in EPA+DHA+DPA associated with a 22 bp increase in telomere length ( $p = 0.07$ ). All results were similar after adjusting for age, gender, and SAD.

### 3.6 Changes in telomere length related to IL-6

Since supplementation reduced serum IL-6 in both low and high dose groups in the parent study (Kiecolt-Glaser et al., 2012), as a secondary analysis we investigated the association between change in telomere length and change in IL-6 for the 101 subjects in the present study who had IL-6 data available at baseline and four months. There was a significant negative correlation between change in telomere length and change in IL-6 (Spearman  $r = -0.20$ ,  $p = 0.05$ ). Of the 51 subjects who experienced telomere lengthening, 61% ( $n=31$ ) had lowered IL-6, compared to 34% ( $n=17$ ) of the 50 who did not experience telomere lengthening ( $p = 0.007$ ).

## 4. Discussion

### 4.1 Intervention-related changes

As previously reported, n-3 PUFA supplementation significantly reduced inflammation in this trial (Kiecolt-Glaser et al., 2012). In these new data, analyses that compared the changes among the n-3 PUFA groups revealed that supplementation also lowered F2-isoprostanes but showed no significant effects related to telomere length or telomerase. However, individuals differ in absorption and metabolism of n-3 PUFA supplements, as well as in adherence, and thus additional planned analyses that used actual changes in the n-6:n-3 PUFA plasma ratios clarified the intervention's impact: lower n-6:n-3 PUFA ratios were associated with longer telomeres at the trial's end. These randomized trial data complement the observational findings from the Heart and Soul Study which showed that slower telomere attrition was reliably related to higher levels of the two key n-3 PUFAs (Farzaneh-Far et al., 2010a). Our data are also in accord with evidence linking higher dietary intake of n-6 PUFAs with shorter telomeres (Cassidy et al., 2010; Kang, 2010).

Telomerase activity level did not change in our sample, in contrast to the changes observed following an intensive three-month lifestyle change program in a different study group - men with early prostate cancer - that included 3 g/day of fish oil (Ornish et al., 2008). That intervention also included dietary change (low-fat and high plant-based), aerobic exercise, and stress management. Further, as that previous study had no non-intervention control group, those data must be interpreted cautiously as regards involvement of n-3 PUFAs.

Depressive symptoms were quite low at baseline in this sample, and did not change (Kiecolt-Glaser et al., 2012). However, prior studies that have linked lower n-3 PUFA



plasma levels and depression suggest a potential benefit for more distressed groups (Appleton et al., 2010; Hibbeln, 1998). Depression and chronic stress have been associated with shorter telomeres (Damjanovic et al., 2007; Epel et al., 2004; Wolkowitz et al., 2010). Depression and chronic stress boost inflammation (Glaser and Kiecolt-Glaser, 2005; Kiecolt-Glaser et al., 2003) as well as oxidative stress (Epel et al., 2004; Wolkowitz et al., 2010), and could speed telomere erosion through these pathways. Accordingly, *n*-3 PUFA supplementation might also slow telomere attrition by enhancing mood in more depressed samples.

Although age-related reductions in telomeres are the average situation, recent studies showed that telomeres can both shorten and elongate *in vivo*, and leukocyte telomere length can change within a period of months (Shlush et al., 2011; Svenson et al., 2011). Alterations in oxidative stress were highlighted as a potential mechanism in two recent reports (Shlush et al., 2011; Svenson et al., 2011). Our data suggest that a dietary intervention that reduces the joint burden of oxidative stress and inflammation may in turn have positive consequences for telomere length.

During aging there is a shift from naïve to memory T-cells, and the latter have shorter telomeres (Svenson et al., 2011). We do not know if the reductions in inflammation and oxidative stress in our *n*-3 PUFA supplemented participants reflected shifts in leukocyte subpopulations that contributed to the telomere changes observed, one limitation of the present study. In addition, a longer supplementation period with additional assessments would have been helpful to better assess the full impact of the intervention on telomere length and telomerase.

It would have been desirable to examine *n*-6 and *n*-3 PUFAs in red blood cells (RBCs) in addition to plasma levels. Circulating PUFA levels reflect the interplay among dietary intake, absorption, and metabolism and are not always strongly correlated with dietary intake of fatty acids (Fusconi et al., 2003; Seierstad et al., 2005). RBC PUFA levels reflect longer-term PUFA consumption as the turn-over is slow and more reliable (Harris, 2008; Harris, 2009). For example, DHA levels in RBCs are thought to indicate dietary fat intake for the past four months, while levels in plasma may only mirror intake from the last few days (Arab, 2003; Sun et al., 2007). However, our intervention spanned four months and serum and plasma proinflammatory cytokines can change in hours (Glaser and Kiecolt-Glaser, 2005); for example, infusion of a fish oil-based lipid emulsion substantially reduced monocyte production of IL-6, TNF- $\alpha$ , IL-1, and IL-8 in response to endotoxin (Mayer et al., 2003). For these reasons, plasma PUFA data were essential to assess recent dietary influences on inflammatory markers in this study.

As described earlier, the *n*-6 and *n*-3 PUFAs compete for key enzymatic pathways, and thus the relative balance is of interest (Simopoulos, 2008). ATTICA, a large health and nutrition survey of healthy Greek adults, showed that higher *n*-6:*n*-3 PUFA plasma ratios were associated with higher TNF- $\alpha$  and IL-6 (Kalogeropoulos et al., 2010). In prior work from our lab, higher levels of depressive symptoms as well as higher *n*-6:*n*-3 PUFA ratios worked together to markedly enhance proinflammatory cytokines beyond the contribution provided by either variable alone (Kiecolt-Glaser et al., 2007).

Our participants' average *n*-6:*n*-3 PUFA ratio at baseline was 10.8 (SD=2.6, range=3.3–18.8), considerably lower than the 14:1 ratio derived from plasma data reported for both the large Nurses' Health Study and the ATTICA cohorts (Kalogeropoulos et al., 2010; Sun et al., 2007). Participants with higher *n*-6:*n*-3 PUFA ratios would have benefitted more because supplementation of poorer diets might have permitted greater positive change. Accordingly,

our data may underestimate the potential impact of the *n*-3 PUFAs for the general population.

## 4.2 Health implications

We found that telomere length increased with decreasing *n*-6:*n*-3 PUFA ratios. These data suggest that rather than just considering the absolute amount of *n*-3 PUFA, the background levels of both the *n*-6 and the *n*-6:*n*-3 PUFAs should also be taken into account for clinical studies or for evaluation of nutritional interventions. For example, the *n*-6:*n*-3 PUFA ratio can be altered by increasing *n*-3 PUFA supplementation, but also by decreasing *n*-6 intake.

Several large studies have linked higher *n*-3 PUFA levels with lower all-cause mortality (Lee et al., 2009; Pottala et al., 2010) including a large 3.5 year trial (Marchioli et al., 2002). The *n*-3 PUFA's anti-inflammatory and antioxidant properties provide one obvious pathway for these reductions in mortality, consistent with the finding that decreases in IL-6 were associated with telomere lengthening in this study. Our data suggest that the *n*-3 PUFAs can impact cell aging in addition to inflammation and oxidative stress. This translational research broadens our understanding of the *n*-3 PUFA's potential therapeutic effects.

Short telomeres predict early disease, and slowing immune cell aging could have broad effects by slowing the onset of age-related diseases. Recent work has demonstrated the causal effect of telomerase deficiency and telomere shortening on cellular health and premature aging and mortality in rodents (Bernardes de Jesus et al., 2012; Jaskelioff et al., 2011; Sahin et al., 2011). In summary, the current study provides compelling initial evidence that lower *n*-6:*n*-3 PUFA ratios may be beneficial for slowing biological aging.

## Acknowledgments

The study was supported in part by NIH grants AG029562, AG038621, UL1RR025755, and CA16058. OmegaBrite (Waltham, MA) supplied the omega-3 PUFA supplement and placebo without charge and without restrictions; OmegaBrite did not influence the design, funding, implementation, interpretation, or publication of the data.

## References

- Intakes of 19 individual fatty acids: Results from 1994–96, continuing survey of food intakes by individuals. U. S. Department of Agriculture, Agricultural Research Service; <http://www.barc.usda.gov/bhnrc/foodsurvey/home.htm>
- Appleton KM, Rogers PJ, Ness AR. Updated systematic review and meta-analysis of the effects of n-3 long-chain polyunsaturated fatty acids on depressed mood. *Am J Clin Nutr.* 2010; 91:757–770. [PubMed: 20130098]
- Arab L. Biomarkers of fat and fatty acid intake. *J Nutr.* 2003; 133(Suppl 3):925S–932S. [PubMed: 12612178]
- Ariel A, Serhan CN. Resolvins and protectins in the termination program of acute inflammation. *Trends in immunology.* 2007; 28:176–183. [PubMed: 17337246]
- Aviv A. Telomeres and human aging: Facts and fibs. *Science of Aging, Knowledge, and Environment.* 2004; 51:pe43.
- Aviv A. Telomeres and human somatic fitness. *Journals of Gerontology Series A-Biological Sciences and Medical Sciences.* 2006; 61:871–873.
- Aviv A, Chen W, Gardner JP, Kimura M, Brimacombe M, Cao XJ, Srinivasan SR, Berenson GS. Leukocyte telomere dynamics: Longitudinal findings among young adults in the Bogalusa Heart Study. *Am J Epidemiol.* 2009; 169:323–329. [PubMed: 19056834]
- Belury MA, Kempa-Steczko A. Conjugated linoleic acid modulates hepatic lipid composition in mice. *Lipids.* 1997; 32:199–204. [PubMed: 9075211]

- Bernardes de Jesus B, Vera E, Schneeberger K, Tejera AM, Ayuso E, Bosch F, Blasco MA. Telomerase gene therapy in adult and old mice delays aging and increases longevity without increasing cancer. *EMBO Molecular Medicine*. 2012; 4:691–704. doi: 610.1002/emmm.201200245. [PubMed: 22585399]
- Blackburn EH. Telomeres and telomerase: Their mechanisms of action and the effects of altering their functions. *FEBS Lett*. 2005; 579:859–862. [PubMed: 15680963]
- Bligh WJ, Dyer EG. A rapid method of total lipid extraction and purification. *Canadian Journal of Biochemical Physiology*. 1959; 37:911–917.
- Brouillette S, Singh RK, Thompson JR, Goodall AH, Samani NJ. White cell telomere length and risk of premature myocardial infarction. *Arterioscler Thromb Vasc Biol*. 2003; 23:842–846. [PubMed: 12649083]
- Buysse DJ, Reynolds CF, Monk TH, Berman SR, Kupfer DJ. Pittsburgh Sleep Quality Index: A new instrument for psychiatric practice and research. *Psychiatry Res*. 1989; 28:193–213. [PubMed: 2748771]
- Calder PC. Polyunsaturated fatty acids and inflammation. *Biochem Soc Trans*. 2005; 33:423–427. [PubMed: 15787620]
- Carrero J, Stenvinkel P, Fellstrom B, Qureshi AR, Lamb K, Heimburger O, Barany P, Radhakrishnan K, Lindholm B, Soveri I, Nordfors L, Shiels PG. Telomere attrition is associated with inflammation, low fetuin-a levels and high mortality in prevalent haemodialysis patients. *J Intern Med*. 2008; 263:302–312. [PubMed: 18070000]
- Cassidy A, De Vivo I, Liu Y, Han J, Prescott J, Hunter DJ, Rimm EB. Associations between diet, lifestyle factors, and telomere length in women. *Am J Clin Nutr*. 2010; 91:1273–1280. [PubMed: 20219960]
- Cawthon RM. Telomere measurement by quantitative PCR. *Nucleic Acids Res*. 2002; 30:e47. [PubMed: 12000852]
- Chan SW, Blackburn EH. Telomerase and ATM/Tel1p protect telomeres from nonhomologous end joining. *Mol Cell*. 2003; 11:1379–1387. [PubMed: 12769860]
- Clasey JL, Bouchard C, Teates CD, Riblett JE, Thorner MO, Hartman ML, Weltman A. The use of anthropometric and dual-energy x-ray absorptiometry (DXA) measures to estimate total abdominal and abdominal visceral fat in men and women. *Obes Res*. 1999; 7:256–264. [PubMed: 10348496]
- Damjanovic AK, Yang Y, Glaser R, Kiecolt-Glaser JK, Nguyen H, Laskowski B, Zou Y, Beversdorf DQ, Weng N-p. Accelerated telomere erosion is associated with a declining immune function of caregivers of Alzheimer's disease patients. *J Immunol*. 2007; 179:4249–4254. [PubMed: 17785865]
- Ehrlebach S, Willeit P, Kiechl S, Willeit J, Reindl M, Schanda K, Kronenberg F, Brandstatter A. Influences on the reduction of relative telomere length over 10 years in the population-based bruneck study: Introduction of a well-controlled high-throughput assay. *Int J Epidemiol*. 2009; 38:1725–1734. [PubMed: 19666704]
- Epel ES, Blackburn EH, Lin J, Dhabhar FS, Adler NE, Morrow JD, Cawthon RM. Accelerated telomere shortening in response to life stress. *Proc Natl Acad Sci U S A*. 2004; 101:17312–17315. [PubMed: 15574496]
- Epel ES, Merkin SS, Cawthon R, Blackburn EH, Adler NE, Pletcher MJ, Seeman TE. The rate of leukocyte telomere shortening predicts mortality from cardiovascular disease in elderly men. *Aging (Milano)*. 2009; 1:81–88.
- Farzaneh-Far R, Harris WS, Garg S, Na B, Whooley MA. Inverse association of erythrocyte n-3 fatty acid levels with inflammatory biomarkers in patients with stable coronary artery disease: The Heart and Soul Study. *Atherosclerosis*. 2009; 205:538–543. [PubMed: 19185299]
- Farzaneh-Far R, Lin J, Epel E, Lapham K, Blackburn E, Whooley MA. Telomere length trajectory and its determinants in persons with coronary artery disease: Longitudinal findings from the Heart and Soul Study. *Plos One*. 2010a; 5:e8612. doi:8610.1371/journal.pone.0008612. [PubMed: 20072607]
- Farzaneh-Far R, Lin J, Epel ES, Harris WS, Blackburn EH, Whooley MA. Association of marine omega-3 fatty acid levels with telomeric aging in patients with coronary heart disease. *J A M A*. 2010b; 303:250–257.

- Ferrucci L, Cherubini A, Bandinelli S, Bartali B, Corsi A, Lauretani F, Martin A, Andres-Lacueva C, Senin U, Guralnik JM. Relationship of plasma polyunsaturated fatty acids to circulating inflammatory markers. *J Clin Endocrinol Metab.* 2006; 91:439–446. [PubMed: 16234304]
- First, M.; Gibbon, M.; Spitzer, R.; Williams, J. User's guide for the Structured Clinical Interview for DSM-IV Axis I Disorders—research version. Biometrics Research Department, New York State Psychiatric Institute; New York, NY: 1996.
- Fusconi E, Pala V, Riboli E, Vineis P, Sacerdote C, Del Pezzo M, Santucci de Magistris M, Palli D, Masala G, Sieri S, Foggetti CE, Giurdanella MC, Tumino R, Krogh V. Relationship between plasma fatty acid composition and diet over previous years in the Italian centers of the European Prospective Investigation into Cancer and Nutrition (EPIC). *Tumori.* 2003; 89:624–635. [PubMed: 14870827]
- Gardner JP, Li SX, Srinivasan SR, Chen W, Kimura M, Lu XB, Berenson GS, Aviv A. Rise in insulin resistance is associated with escalated telomere attrition. *Circulation.* 2005; 111:2171–2177. [PubMed: 15851602]
- Glaser R, Kiecolt-Glaser JK. Stress-induced immune dysfunction: Implications for health. *Nature Reviews Immunology.* 2005; 5:243–251.
- Harris WS. The omega-3 index as a risk factor for coronary heart disease. *Am J Clin Nutr.* 2008; 87:1997S–2002. [PubMed: 18541601]
- Harris WS. The omega-3 index: From biomarker to risk marker to risk factor. *Curr Atheroscler Rep.* 2009; 11:411–417. [PubMed: 19852881]
- Hibbeln JR. Fish consumption and major depression. *Lancet.* 1998; 351:1213. [PubMed: 9643729]
- Jaskieloff M, Muller FL, Paik JH, Thomas E, Jiang S, Adams AC, Sahin E, Kost-Alimova M, Protopopov A, Cadinanos J, Horner JW, Maratos-Flier E, DePinho RA. Telomerase reactivation reverses tissue degeneration in aged telomerase-deficient mice. *Nature.* 2011; 469:102–U1700. [PubMed: 21113150]
- Kalogeropoulos N, Panagiotakos DB, Pitsavos C, Chrysoshoou C, Rousinou G, Toutouza M, Stefanadis C. Unsaturated fatty acids are inversely associated and n-6/n-3 ratios are positively related to inflammation and coagulation markers in plasma of apparently healthy adults. *Clin Chim Acta.* 2010; 411:584–591. [PubMed: 20097190]
- Kang JX. Differential effects of omega-6 and omega-3 fatty acids on telomere length. *Am J Clin Nutr.* 2010; 92:1276–1277. [PubMed: 20844067]
- Kiecolt-Glaser JK, Belury MA, Andridge R, Malarkey WB, Glaser R. Omega-3 supplementation lowers inflammation and anxiety in medical students: A randomized controlled trial. *Brain Behav Immun.* 2011; 25:1725–1734. [PubMed: 21784145]
- Kiecolt-Glaser JK, Belury MA, Andridge R, Malarkey WB, Hwang BS, Glaser R. Omega-3 supplementation lowers inflammation in healthy middle-aged and older adults: A randomized controlled trial. *Brain Behav Immun.* 2012; 26:988–995. [PubMed: 22640930]
- Kiecolt-Glaser JK, Belury MA, Porter K, Beversdorf D, Lemeshow S, Glaser R. Depressive symptoms, omega-6:omega-3 fatty acids, and inflammation in older adults. *Psychosom Med.* 2007; 69:217–224. [PubMed: 17401057]
- Kiecolt-Glaser JK, Preacher KJ, MacCallum RC, Atkinson C, Malarkey WB, Glaser R. Chronic stress and age-related increases in the proinflammatory cytokine IL-6. *Proc Natl Acad Sci U S A.* 2003; 100:9090–9095. [PubMed: 12840146]
- Kimura M, Hjelmborg JVB, Gardner JP, Bathum L, Brimacombe M, Lu XB, Christiansen L, Vaupel JW, Aviv A, Christensen K. Telomere length and mortality: A study of leukocytes in elderly Danish twins. *Am J Epidemiol.* 2008; 167:799–806. [PubMed: 18270372]
- Lee JH, O'Keefe JH, Lavie CJ, Harris WS. Omega-3 fatty acids: Cardiovascular benefits, sources and sustainability. *Nature Reviews Cardiology.* 2009; 6:753–758.
- Lin J, Epel E, Cheon J, Kroenke C, Sinclair E, Bigos M, Wolkowitz O, Mellon S, Blackburn E. Analyses and comparisons of telomerase activity and telomere length in human T and B cells: Insights for epidemiology of telomere maintenance. *J Immunol Methods.* 2010a; 352:71–80. [PubMed: 19837074]
- Lin PY, Huang SY, Su KP. A meta-analytic review of polyunsaturated fatty acid compositions in patients with depression. *Biol Psychiatry.* 2010b; 68:140–147. [PubMed: 20452573]

- Lipsey M, Soderberg E, Basu S, Larsson A, Sjolín J, Astrom M, Eriksson MB. F-2-isoprostane, inflammation, cardiac function and oxygenation in the endotoxaemic pig. *Prostaglandins Leukot Essent Fatty Acids*. 2008; 78:209–217. [PubMed: 18387796]
- Marchioli R, Barzi F, Bomba E, Chieffo C, Di Gregorio D, Di Mascio R, Franzosi MG, Geraci E, Levantesi G, Maggioni AP, Mantini L, Marfisi RM, Mastrogiuseppe G, Mininni N, Nicolosi GL, Santini M, Schweiger C, Tavazzi L, Tognoni G, Tucci C, Valagussa F, Investigators GIP. Early protection against sudden death by n-3 polyunsaturated fatty acids after myocardial infarction - time-course analysis of the results of the Gruppo Italiano per lo Studio della Sopravvivenza nell'Infarto Miocardico (GISSI)-Prevenzione. *Circulation*. 2002; 105:1897–1903. [PubMed: 11997274]
- Mayer K, Meyer S, Reinholz-Muhly M, Maus U, Merfels M, Lohmeyer J, Grimminger F, Seeger W. Short-time infusion of fish oil-based lipid emulsions, approved for parenteral nutrition, reduces monocyte proinflammatory cytokine generation and adhesive interaction with endothelium in humans. *J Immunol*. 2003; 171:4837–4843. [PubMed: 14568963]
- Milne, GL.; Yin, HY.; Brooks, JD.; Sanchez, S.; Roberts, LJ.; Morrow, JD. Quantification of F2-isoprostanes in biological fluids and tissues as a measure of oxidant stress. In: Brown, HA., editor. *Lipidomics and bioactive lipids: Specialized analytical methods and lipids in disease*. Elsevier Academic Press Inc; San Diego: 2007. p. 113-126.
- Mori TA, Dunstan DW, Burke V, Croft KD, Rivera JH, Beilin LJ, Puddey IB. Effect of dietary fish and exercise training on urinary F-2-isoprostane excretion in non-insulin-dependent diabetic patients. *Metabolism-Clinical and Experimental*. 1999; 48:1402–1408. [PubMed: 10582548]
- Nalsen C, Vessby B, Berglund L, Uusitupa M, Hermansen K, Riccardi G, Rivellese A, Storlien L, Erkkila A, Yla-Herttuala S, Tapsell L, Basu S. Dietary (n-3) fatty acids reduce plasma F-2-isoprostanes but not prostaglandin F-2 alpha in healthy humans. *J Nutr*. 2006; 136:1222–1228. [PubMed: 16614408]
- Nordfjall K, Svenson U, Norrback KF, Adolfsson R, Lenner P, Roos G. The individual blood cell telomere attrition rate is telomere length dependent. *PLoS Genet*. 2009; 5:e1000375. DOI: 1000310.1001371/journal.pgen.1000375. [PubMed: 19214207]
- Ornish D, Lin J, Daubenmier J, Weidner G, Epel E, Kemp C, Magbanua MJM, Marlin R, Yglecias L, Carroll PR, Blackburn EH. Increased telomerase activity and comprehensive lifestyle changes: A pilot study. *The Lancet Oncology*. 2008; 9:1048–1057. [PubMed: 18799354]
- Patterson RE, Kristal AR, Carter RA, Fels-Tinker LF, Bolton MP, Argurs-Collins T. Measurement characteristics of the Women's Health Initiative Food Frequency Questionnaire. *Ann Epidemiol*. 1999; 9:178–187. [PubMed: 10192650]
- Pottala JV, Garg S, Cohen BE, Whooley MA, Harris WS. Blood eicosapentaenoic and docosahexaenoic acids predict all-cause mortality in patients with stable coronary heart disease: The Heart and Soul Study. *Circ-Cardiovasc Qual Outcomes*. 2010; 3:406–412. [PubMed: 20551373]
- Radloff LS. The CES-D scale: A self-report depression scale for research in the general population. *Applied Psychological Measurement*. 1977; 1:385–401.
- Sahin E, Colla S, Liesa M, Moslehi J, Muller FL, Guo MR, Cooper M, Kotton D, Fabian AJ, Walkey C, Maser RS, Tonon G, Foerster F, Xiong R, Wang YA, Shukla SA, Jaskelioff M, Martin ES, Heffernan TP, Protopopov A, Ivanova E, Mahoney JE, Kost-Alimova M, Perry SR, Bronson R, Liao RL, Mulligan R, Shirihai OS, Chin L, DePinho RA. Telomere dysfunction induces metabolic and mitochondrial compromise. *Nature*. 2011; 470:359–365. [PubMed: 21307849]
- Seierstad SL, Seljeflot I, Johansen O, Hansen R, Haugen M, Rosenlund G, Froyland L, Arnesen H. Dietary intake of differently fed salmon; the influence on markers of human atherosclerosis. *Eur J Clin Invest*. 2005; 35:52–59. [PubMed: 15638820]
- Shantha NC, Decker EA, Hennig B. Comparison of methylation methods for the quantitation of conjugated linoleic acid isomers. *J AOAC Int*. 1993; 76:644–649.
- Shlush LI, Skorecki KL, Itzkovitz S, Yehezkel S, Segev Y, Shachar H, Berkovitz R, Adir Y, Vulto I, Lansdorpd PM, Selig S. Telomere elongation followed by telomere length reduction, in leukocytes from divers exposed to intense oxidative stress - implications for tissue and organismal aging. *Mech Ageing Dev*. 2011; 132:123–130. [PubMed: 21320523]

- Sijben JWC, Calder PC. Differential immunomodulation with long-chain n-3 PUFA in health and chronic disease. *Proc Nutr Soc.* 2007; 66:237–259. [PubMed: 17466105]
- Simopoulos AP. The importance of the omega-6/omega-3 fatty acid ratio in cardiovascular disease and other chronic diseases. *Exp Biol Med.* 2008; 233:674–688.
- Stewart AL, Mills KM, King AC, Haskell WL, Gillis D, Ritter PL. CHAMPS physical activity questionnaire for older adults: Outcomes for interventions. *Med Sci Sports Exerc.* 2001; 33:1126–1141. [PubMed: 11445760]
- Stoll AL, Damico KE, Daly BP, Severus WE, Marangell LB. Methodological considerations in clinical studies of omega 3 fatty acids in major depression and bipolar disorder. *World Rev Nutr Diet.* 2001; 88:58–67. [PubMed: 11935971]
- Sun Q, Ma J, Campos H, Hankinson SE, Hu FB. Comparison between plasma and erythrocyte fatty acid content as biomarkers of fatty acid intake in US women. *The American Journal of Clinical Nutrition.* 2007; 86:74–81. [PubMed: 17616765]
- Svenson U, Nordfjall K, Baird D, Roger L, Osterman P, Hellenius ML, Roos G. Blood cell telomere length is a dynamic feature. *PLoS ONE.* 2011; 6:e21485. doi:21410.21371/journal.pone.0021485. [PubMed: 21720548]
- Valdes AM, Andrew T, Gardner JP, Kimura M, Oelsner E, Cherkas LF, Aviv A, Spector TD. Obesity, cigarette smoking, and telomere length in women. *Lancet.* 2005; 366:662–664. [PubMed: 16112303]
- Wolkowitz OM, Epel ES, Reus VI, Mellon SH. Depression gets old fast: Do stress and depression accelerate cell aging? *Depress Anxiety.* 2010; 27:327–338. [PubMed: 20376837]

**Table 1**

Baseline characteristics of study population, by intervention group

|   | Placebo (n=31)      | 1.25 g/day n-3 (n=40) | 2.5 g/day n-3 (n=35) |
|---|---------------------|-----------------------|----------------------|
| Age, mean (SD), years                         | 51.2 (8.9)          | 50.3 (7.8)            | 50.6 (6.5)           |
| Female, No. (%)                               | 23 (74%)            | 24 (60%)              | 22 (63%)             |
| Race, No. (%)                                 |                     |                       |                      |
| White   | 23 (74%)            | 33 (83%)              | 27 (77%)             |
| Black   | 4 (13%)             | 5 (13%)               | 7 (20%)              |
| Asian   | 2 (6%)              | 1 (3%)                | 1 (3%)               |
| Other   | 2 (6%)              | 1 (3%)                | 0 (0%)               |
| Body mass index, mean (SD), kg/m <sup>2</sup> | 31.1 (4.8)          | 31.7 (4.5)            | 30.7 (3.8)           |
| Sagittal abdominal diameter, mean (SD), cm    | 23.1 (3.1)          | 23.4 (3.1)            | 22.9 (2.4)           |
| Telomere length at baseline, base pairs       |                     |                       |                      |
| N   | 31                  | 40                    | 35                   |
| Mean (SD)                                     | 5866 (430)          | 5809 (374)            | 5916 (432)           |
| Median (IQR)                                  | 5810 (5588–6257)    | 5782 (5566–6092)      | 5838 (5681–6280)     |
| Range   | 4981–6531           | 4963–6612             | 5042–6764            |
| Telomerase at baseline, activity/10,000 cells |                     |                       |                      |
| N   | 27                  | 36                    | 31                   |
| Mean (SD)                                     | 8.5 (4.2)           | 8.2 (4.4)             | 7.9 (3.3)            |
| Median (IQR)                                  | 7.0 (5.8–10.9)      | 7.1 (5.8–9.8)         | 7.4 (5.2–10.5)       |
| Range   | 2.0–20.3            | 2.1–25.5              | 2.6–16.6             |
| F2-isoprostanes at baseline, ng/ml            |                     |                       |                      |
| N   | 27                  | 38                    | 32                   |
| Mean (SD)                                     | 0.036 (0.017)       | 0.037 (0.015)         | 0.031 (0.012)        |
| Median (IQR)                                  | 0.032 (0.025–0.044) | 0.033 (0.026–0.045)   | 0.032 (0.024–0.036)  |
| Range   | 0.017–0.087         | 0.01–0.069            | 0.011–0.081          |

**Table 2****Fatty Acid Composition of Dietary Oil Supplements (% Fatty Acid)**

| Fatty Acid                               | Name                        | Placebo | Supplement |
|--|-----------------------------|---------|------------|
| C14:0                                    | myristic acid               | 6.4     | 0.1        |
| C16:0                                    | palmitic acid               | 19.6    | 0.1        |
| C16:1n7                                  | palmitoleic acid            | 0.4     | 0.1        |
| C18:0                                    | stearic acid                | 3.1     | 0.5        |
| C18:1n9                                  | oleic acid                  | 43.5    | 0.7        |
| C18:1n7                                  | vaccenic acid               | 1.4     | 0.4        |
| C18:2n6                                  | linoleic acid               | 20.4    | 0.2        |
| C18:3n6                                  | gamma linolenic acid        | 0.0     | 0.7        |
| C18:3n3                                  | alpha linolenic acid        | 3.3     | 0.2        |
| C18:4n3                                  | stearidonic acid            | 0.1     | 6.9        |
| C20:1n9                                  | cetoleic acid               | 0.2     | 0.4        |
| C20:2n6                                  | eicosadienoic acid          | 0.0     | 0.1        |
| C20:3n6                                  | dihomo-gamma-linolenic acid | 0.0     | 0.1        |
| C20:4n6                                  | arachidonic acid            | 0.1     | 3.5        |
| C20:4n3                                  | eicosatetraenoic acid       | 0.0     | 1.5        |
| C20:5n3                                  | eicosapentaenoic acid       | 1.2     | 75.0       |
| C22:4n6                                  | adrenic acid                | 0.0     | 0.0        |
| C22:5n3                                  | docosapentaenoic acid       | 0.0     | 0.8        |
| C22:6n3                                  | docosahexaenoic acid        | 0.2     | 8.9        |
| Total Reported                           |                             | 100     | 100        |
| Saturated Fatty Acids <sup>1</sup>       |                             | 29.1    | 0.7        |
| Monounsaturated Fatty Acids <sup>2</sup> |                             | 45.3    | 1.2        |
| Omega 3 Fatty Acids <sup>3</sup>         |                             | 4.8     | 93.3       |
| Omega 6 Fatty Acids <sup>4</sup>         |                             | 20.5    | 4.6        |
| n-6/n-3ratio <sup>5</sup>                |                             | 4.27    | 0.05       |

<sup>1</sup>C14:0, C16:0, C18:0

<sup>2</sup>C16:1n7, C18:1n7, C18:1n9

<sup>3</sup>Sum of (C18:3n3+C18:4n3+C20:4n3+C20:5n3+C22:5n3+C22:6n3)

<sup>4</sup>Sum of (C18:2n6+C18:3n6+C20:2n6+C20:3n6+C20:4n6+C22:4n6)

<sup>5</sup>Sum of (C18:2n6+C18:3n6+C20:2n6+C20:3n6+C20:4n6+C22:4n6)/Sum of (C18:3n3+C18:4n3+C20:4n3+C20:5n3+C22:5n3+C22:6n3)



Table 3

Plasma fatty acids<sup>a</sup>, by intervention group

|                                      | Baseline    | P Value <sup>2</sup> | 4 months    | P Value <sup>2</sup> | Change, 0 to 4 months | P for change <sup>3</sup> | comparison of changes <sup>2</sup> |
|--------------------------------------|-------------|----------------------|-------------|----------------------|-----------------------|---------------------------|------------------------------------|
| <i>Saturated Fatty Acids</i>         |             |                      |             |                      |                       |                           |                                    |
| myristic acid c14:0                  |             | 0.29                 |             | 0.94                 |                       |                           | 0.21                               |
| Placebo                              | 0.92 (0.38) |                      | 0.91 (0.33) |                      | -0.006 (0.42)         | 0.93                      |                                    |
| 1.25 g/day n-3                       | 1.0 (0.47)  |                      | 0.89 (0.33) |                      | -0.14 (0.45)          | 0.06                      |                                    |
| 2.5 g/day n-3                        | 0.86 (0.52) |                      | 0.91 (0.49) |                      | 0.054 (0.56)          | 0.58                      |                                    |
| palmitic acid c16:0                  |             | 0.04                 |             | 0.93                 |                       |                           | 0.07                               |
| Placebo                              | 23 (2.6)    |                      | 23 (3.0)    |                      | 0.28 (3.3)            | 0.64                      |                                    |
| 1.25 g/day n-3                       | 24 (2.7)    |                      | 23 (2.5)    |                      | -0.55 (3.2)           | 0.28                      |                                    |
| 2.5 g/day n-3                        | 22 (2.8)    |                      | 23 (3.0)    |                      | 1.2 (3.3)             | 0.04                      |                                    |
| palmitoleic acid c16:1n-7            |             | 0.33                 |             | 0.06                 |                       |                           | 0.03                               |
| Placebo                              | 1.7 (0.56)  |                      | 1.8 (0.61)  |                      | 0.13 (0.59)           | 0.23                      |                                    |
| 1.25 g/day n-3                       | 1.8 (0.64)  |                      | 1.5 (0.56)  |                      | -0.28 (0.72)          | 0.02                      |                                    |
| 2.5 g/day n-3                        | 1.5 (0.80)  |                      | 1.5 (0.60)  |                      | -0.012 (0.60)         | 0.91                      |                                    |
| <i>Omega-6 Fatty Acids</i>           |             |                      |             |                      |                       |                           |                                    |
| linoleic acid c18:2n-6               |             | 0.005                |             | 0.69                 |                       |                           | 0.06                               |
| Placebo                              | 30 (3.9)    |                      | 30 (5.3)    |                      | -0.47 (5.5)           | 0.63                      |                                    |
| 1.25 g/day n-3                       | 28 (4.1)    |                      | 29 (4.4)    |                      | 0.7 (4.3)             | 0.29                      |                                    |
| 2.5 g/day n-3                        | 31 (4.7)    |                      | 29 (4.0)    |                      | -2.1 (5.4)            | 0.03                      |                                    |
| gamma linolenic acid c18:3n-6        |             | 0.58                 |             | 0.26                 |                       |                           | 0.08                               |
| Placebo                              | 0.45 (0.16) |                      | 0.47 (0.22) |                      | 0.019 (0.19)          | 0.57                      |                                    |
| 1.25 g/day n-3                       | 0.49 (0.18) |                      | 0.44 (0.18) |                      | -0.06 (0.2)           | 0.05                      |                                    |
| 2.5 g/day n-3                        | 0.47 (0.13) |                      | 0.40 (0.16) |                      | -0.074 (0.17)         | 0.01                      |                                    |
| dihomo-gamma linolenic acid c20:3n-6 |             | 0.43                 |             | 0.001                |                       |                           | 0.0002                             |
| Placebo                              | 1.7 (0.36)  |                      | 1.8 (0.46)  |                      | 0.12 (0.43)           | 0.14                      |                                    |
| 1.25 g/day n-3                       | 1.9 (0.40)  |                      | 1.7 (0.46)  |                      | -0.20 (0.40)          | 0.00                      |                                    |
| 2.5 g/day n-3                        | 1.8 (0.54)  |                      | 1.4 (0.37)  |                      | -0.31 (0.44)          | 0.0002                    |                                    |
| arachidonic acid c20:4n-6            |             | 0.52                 |             | 0.64                 |                       |                           | 0.05                               |
| Placebo                              | 7.7 (2.7)   |                      | 7.5 (2.5)   |                      | -0.25 (1.8)           | 0.44                      |                                    |

|                                      | Baseline    | P Value <sup>2</sup> | 4 months    | P Value <sup>2</sup> | Change, 0 to 4 months | P for change <sup>3</sup> | comparison of changes <sup>2</sup> |
|--------------------------------------|-------------|----------------------|-------------|----------------------|-----------------------|---------------------------|------------------------------------|
| 1.25 g/day n-3                       | 7.3 (1.9)   |                      | 7.2 (1.7)   |                      | -0.115 (1.1)          | 0.53                      |                                    |
| 2.5 g/day n-3                        | 7.9 (2.5)   |                      | 7.0 (2.0)   |                      | -0.95 (1.6)           | 0.001                     |                                    |
| <i>Omega-3 Fatty Acids</i>           |             |                      |             |                      |                       |                           |                                    |
| alpha linolenic acid c18:3n-3        |             | 0.26                 |             | 0.81                 |                       |                           | 0.12                               |
| Placebo                              | 0.69 (0.23) |                      | 0.68 (0.18) |                      | -0.01 (0.21)          | 0.78                      |                                    |
| 1.25 g/day n-3                       | 0.76 (0.27) |                      | 0.65 (0.15) |                      | -0.11 (0.26)          | 0.009                     |                                    |
| 2.5 g/day n-3                        | 0.67 (0.24) |                      | 0.65 (0.26) |                      | -0.016 (0.23)         | 0.67                      |                                    |
| stearidonic acid c18:4n-3            |             | 0.45                 |             | 0.80                 |                       |                           | 0.95                               |
| Placebo                              | 0.38 (0.15) |                      | 0.39 (0.20) |                      | 0.012 (0.25)          | 0.80                      |                                    |
| 1.25 g/day n-3                       | 0.41 (0.17) |                      | 0.44 (0.39) |                      | 0.0252 (0.33)         | 0.63                      |                                    |
| 2.5 g/day n-3                        | 0.44 (0.24) |                      | 0.44 (0.36) |                      | -0.0016 (0.44)        | 0.98                      |                                    |
| eicosatetraenoic acid c20:4n-3       |             | 0.83                 |             | 0.07                 |                       |                           | 0.50                               |
| Placebo                              | 0.17 (0.10) |                      | 0.16 (0.08) |                      | -0.010 (0.14)         | 0.68                      |                                    |
| 1.25 g/day n-3                       | 0.18 (0.09) |                      | 0.19 (0.10) |                      | 0.01 (0.1)            | 0.65                      |                                    |
| 2.5 g/day n-3                        | 0.18 (0.08) |                      | 0.21 (0.09) |                      | 0.027 (0.13)          | 0.23                      |                                    |
| eicosapentaenoic acid (EPA) c20:5n-3 |             | 0.52                 |             | <.0001               |                       |                           | <.0001                             |
| Placebo                              | 0.48 (0.17) |                      | 0.74 (0.45) |                      | 0.26 (0.40)           | 0.001                     |                                    |
| 1.25 g/day n-3                       | 0.53 (0.21) |                      | 1.86 (0.81) |                      | 1.3 (0.73)            | <.0001                    |                                    |
| 2.5 g/day n-3                        | 0.55 (0.36) |                      | 3.42 (1.33) |                      | 2.9 (1.4)             | <.0001                    |                                    |
| docosapentaenoic acid (DPA) c22:5n-3 |             | 0.19                 |             | <.0001               |                       |                           | <.0001                             |
| Placebo                              | 0.53 (0.14) |                      | 0.59 (0.12) |                      | 0.056 (0.15)          | 0.05                      |                                    |
| 1.25 g/day n-3                       | 0.60 (0.13) |                      | 1.01 (0.31) |                      | 0.42 (0.31)           | <.0001                    |                                    |
| 2.5 g/day n-3                        | 0.56 (0.17) |                      | 1.19 (0.31) |                      | 0.62 (0.31)           | <.0001                    |                                    |
| docosahexaenoic acid (DHA) c22:6n-3  |             | 0.66                 |             | 0.0001               |                       |                           | <.0001                             |
| Placebo                              | 1.5 (0.58)  |                      | 1.6 (0.64)  |                      | 0.061 (0.47)          | 0.47                      |                                    |
| 1.25 g/day n-3                       | 1.4 (0.59)  |                      | 2.0 (0.70)  |                      | 0.59 (0.46)           | <.0001                    |                                    |
| 2.5 g/day n-3                        | 1.5 (0.62)  |                      | 2.2 (0.48)  |                      | 0.71 (0.67)           | <.0001                    |                                    |
| <i>Totals and n-6:n-3 Ratio</i>      |             |                      |             |                      |                       |                           |                                    |
| Total n-3                            |             | 0.74                 |             | <.0001               |                       |                           | <.0001                             |
| Placebo                              | 3.8 (0.82)  |                      | 4.1 (0.93)  |                      | 0.37 (0.77)           | 0.01                      |                                    |
| 1.25 g/day n-3                       | 3.9 (0.8)   |                      | 6.2 (1.6)   |                      | 2.3 (1.4)             | <.0001                    |                                    |

|                | Baseline  | P Value <sup>2</sup> | 4 months  | P Value <sup>2</sup> | Change, 0 to 4 months | P for change <sup>3</sup> | comparison of changes <sup>2</sup> |
|----------------|-----------|----------------------|-----------|----------------------|-----------------------|---------------------------|------------------------------------|
| 2.5 g/day n-3  | 3.9 (1.1) |                      | 8.2 (1.8) |                      | 4.2 (2.1)             | <.0001                    |                                    |
| Total n-6      |           | 0.01                 |           | 0.43                 |                       |                           | 0.01                               |
| Placebo        | 41 (5.4)  |                      | 40 (6.8)  |                      | -0.55 (6.2)           | 0.62                      |                                    |
| 1.25 g/day n-3 | 38 (5.0)  |                      | 39 (5.0)  |                      | 0.27 (4.7)            | 0.72                      |                                    |
| 2.5 g/day n-3  | 42 (5.9)  |                      | 39 (5.1)  |                      | -3.6 (5.9)            | 0.001                     |                                    |
| n-6:n-3 Ratio  |           | 0.07                 |           | <.0001               |                       |                           | <.0001                             |
| Placebo        | 11 (2.0)  |                      | 10 (2.8)  |                      | -0.97 (2.7)           | 0.06                      |                                    |
| 1.25 g/day n-3 | 10 (2.0)  |                      | 6.8 (2.1) |                      | -3.4 (2.2)            | <.0001                    |                                    |
| 2.5 g/day n-3  | 11 (3.1)  |                      | 5.0 (1.6) |                      | -6.4 (3.4)            | <.0001                    |                                    |

Units: Percent of total fatty acids

<sup>1</sup> All values are mean (SD)

<sup>2</sup> ANOVA

<sup>3</sup> Paired t-tests within group

\$watermark-text

\$watermark-text

\$watermark-text

**Table 4**

Estimated change in outcomes (4 months minus baseline) by intervention group, adjusted for baseline outcome levels.

| Outcome                       | Placebo              | 1.25 g/day n=3         | 2.5 g/day n=3          | P-values for group comparisons* |                      |                  |
|-------------------------------|----------------------|------------------------|------------------------|---------------------------------|----------------------|------------------|
|                               |                      |                        |                        | Low Dose vs Placebo             | High Dose vs Placebo | High vs Low Dose |
| Change in Telomere length     | -43 (-131, 46)       | 21 (-57, 99)           | 50 (-33, 133)          | 0.53                            | 0.29                 | 0.87             |
| Change in ln(Telomerase)      | 0.066 (-0.11, 0.24)  | 0.10 (-0.045, 0.25)    | 0.040 (-0.12, 0.20)    | 0.94                            | 0.97                 | 0.83             |
| Change in ln(F2-isoprostanes) | 0.073 (-0.021, 0.17) | -0.094 (-0.17, -0.014) | -0.086 (-0.17, 0.0009) | 0.02                            | 0.04                 | 0.99             |

Units: Telomere length = base pairs; Telomerase = activity/10000 cells; F2-isoprostanes = ng/ml

Numbers in parentheses are 95% confidence intervals.

\* Tukey-Kramer adjustment for multiple comparisons

Sample sizes: Telomerase, n=94; Telomere length, n=106; F2-isoprostanes, n=97

**Table 5**

Linear regression analysis for change in telomere length with change in n-6:n-3 fatty acid plasma ratio, controlling for baseline telomere length.

| <b>Effect</b>                              | <b>Estimate</b> | <b>95% CI</b>   | <b>P-value</b> |
|--|-----------------|-----------------|----------------|
| Intercept                                  | 1040            | (296, 1785)     | 0.007          |
| Telomere length, baseline                  | -0.15           | (-0.27, -0.031) | 0.01           |
| n-6:n3 fatty acids, baseline               | -21             | (-44, 2.0)      | 0.07           |
| Decrease in n6:n3 fatty acids <sup>a</sup> | 20              | (4, 36)         | 0.02           |

Units: telomere length = base pairs.

Regression model with change in telomere length (4 months minus baseline) as the outcome

<sup>a</sup>Decrease in *n*-6:*n*-3 PUFA ratio is calculated as baseline minus 4 months so that a positive value is a decrease in *n*-6:*n*-3 PUFA ratio.